Message :
Required fields
TOKYO, July 29, 2021 /PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, Biogen ) today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021 following 18 months of treatment in the open-label extension (OLE) of the Phase 2b proof-of-concept study in subjects with early Alzheimer s disease (AD) (Mild Cognitive Impairment [MCI] due to AD and mild AD) at the Alzheimer s Association International Conference (AAIC) held in Denver, Colo., United States and virtually from July 26 to 30, 2021 (Presentation No.: 57780).
Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biogen Inc : Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer s Disease at AAIC 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.